Table 1.
Demographic and clinical characteristics of patients.
| Total (n = 164) | No cancer (n = 70) | Cancer (n = 94) | P value | csPCa (n = 68) | Others* (n = 96) | P value | |
|---|---|---|---|---|---|---|---|
| Age, years old | 67.0 (62.0–71.0) | 66.0 (59.0–69.0) | 69.0 (63.8–74.0) | < 0.001 | 69.0 (63.3–74.8) | 66.0 (60.5–69.0) | < 0.001 |
| PNB, N (%) | 46.0 (28.0) | 29.0 (41.4) | 17.0 (18.1) | 0.001 | 10.0 (14.7) | 36.0 (37.5) | 0.001 |
| Abnormal DRE, N (%) | 49.0 (32.5) | 6.0 (9.4) | 43.0 (49.4) | < 0.001 | 36.0 (52.9) | 13.0 (13.5) | < 0.001 |
| Prostate volume, ml | 53.2 (41.0–69.4) | 64.9 (43.6–80.3) | 48.5 (37.1–61.6) | < 0.001 | 46.8 (36.9–61.8) | 56.8 (43.2–77.1) | 0.005 |
| PSAD, ng/ml2 | 0.16 (0.10–0.24) | 0.13 (0.08–0.18) | 0.20 (0.13–0.32) | < 0.001 | 0.20 (0.13–0.41) | 0.14 (0.09–0.21) | < 0.001 |
| tPSA, ng/ml | 9.05 (6.12–12.58) | 8.39 (4.83–12.40) | 9.08 (6.80–13.43) | 0.062 | 9.05 (7.37–15.05) | 9.02 (5.17–11.96) | 0.020 |
| %fPSA | 0.15 (0.11–0.21) | 0.18 (0.13–0.24) | 0.13 (0.10–0.18) | < 0.001 | 0.12 (0.10–0.17) | 0.17 (0.12–0.23) | 0.001 |
| p2PSA, pg/ml | 20.23 (14.35–30.95) | 16.17 (11.18–23.66) | 22.85 (16.18–38.66) | < 0.001 | 25.74 (16.28–47.08) | 16.69 (12.50–24.00) | < 0.001 |
| %p2PSA | 1.60 (1.29–2.09) | 1.39 (1.05–1.70) | 1.79 (1.46–2.22) | < 0.001 | 1.94 (1.57–2.49) | 1.41 (1.11–1.76) | < 0.001 |
| PHI | 44.87 (36.05–61.79) | 37.70 (29.70–45.12) | 54.62 (41.63–75.71) | < 0.001 | 58.26 (47.46–94.34) | 38.92 (31.81–45.38) | < 0.001 |
All values given as median (IQR) and number (%).
csPCa, clinically significant prostate cancer; PNB, previous negative biopsy; PSA, prostate-specific antigen; PSAD, PSA density; tPSA, total PSA; fPSA, free PSA; %fPSA, fPSA to tPSA ratio; p2PSA, [-2]pro PSA; %p2PSA, p2PSA to fPSA ratio; PHI, Prostate Health Index.
Others*: no cancer + Gleason sum 6 prostate cancer.